Renal Cell Carcinoma

Deferred Cytoreductive Nephrectomy Plus Sunitinib Bests Immediate Surgery in RCC

September 22, 2020

In a post hoc analysis of the randomized phase 3 SURTIME trial of patients with metastatic renal cell carcinoma, early treatment with sunitinib demonstrated better control over the disease as well as detection of progression before planned cytoreductive nephrectomy.

A 58-Year-Old Man With Advanced Renal Cell Carcinoma

September 22, 2020

Robert Alter, MD, of John Theurer Cancer Center, describes the rationale for treating a 58-year-old male with advanced renal cell carcinoma with the combination of lenvatinib and everolimus following progression on first-line therapy.

Cabozantinib Doublet Achieves Early Clinical Activity in Advanced ccRCC

September 21, 2020

Patients with advanced clear cell renal cell carcinoma treated with cabozantinib in combination with atezolizumab in the phase 1b COSMIC-021 study, had promising clinical activity, according to results from the study presented during the 2020 European Society of Medical Oncology Virtual Congress.

Molecularly-Guided Therapy Improves Responses in mRCC

September 21, 2020

The use of molecularly-directed frontline therapy enriched responses in patients with metastatic clear cell renal cell carcinoma, demonstrating clinical evidence to support further use, according to findings from the noncomparative, phase 2, biomarker-driven BIONIKK trial.

Durable Benefit Observed at 4 Years With Nivolumab Plus Ipilimumab in Advanced RCC

September 19, 2020

At 4 years of follow-up, nivolumab and ipilimumab in combination as first-line therapy of advanced renal cell carcinoma demonstrated durable benefit versus sunitinib, according to research presented at the 2020 ESMO Virtual Congress.

Frontline Nivolumab Plus Cabozantinib Significantly Improves Survival in Renal Cell Carcinoma

September 19, 2020

Frontline nivolumab in combination with cabozantinib demonstrated a 49% reduction in the risk of disease progression or death as treatment of patients with advanced renal cell carcinoma.

Real-World Study of Nivolumab in RCC Reinforces CheckMate Data

September 16, 2020

Real-world trial results demonstrated nivolumab had comparable overall survival results with those observed in the phase 3 CheckMate 025 study as treatment of patients with advanced renal cell carcinoma who received 1 or more prior lines of therapy.

Data Support Use of Tivozanib in Patients With Advanced Renal Cell Carcinoma

September 09, 2020

Ulka Vaishampayan, MD, discusses the use of tivozanib as treatment of patients with advanced renal cell carcinoma, based on supportive data in the TIVO-3 clinical trial.

Nivolumab/Ipilimumab Established as New Standard in Frontline sRCC

September 08, 2020

The combination of nivolumab plus ipilimumab demonstrated long-term survival and response benefits as treatment of poor- to intermediate-risk patients with advanced renal cell carcinoma with sarcomatoid features compared with sunitinib, according to published results from the phase 3 CheckMate 214 clinical trial.

FDA Approval Sought for Cabozantinib/Nivolumab in Advanced RCC

August 24, 2020

A supplemental New Drug Application was submitted to the FDA for cabozantinib plus nivolumab as treatment of patients with advanced renal cell carcinoma.